Indications for Use:

Rheumatoid Arthritis

• In combination with methotrexate, etanercept is prescribed for adults with moderate to severe active rheumatoid arthritis who have had an inadequate response to basic anti-inflammatory drugs (DMARDs), including methotrexate.
• Etanercept may be used as monotherapy in cases of methotrexate ineffectiveness or intolerance.
• It is indicated for the treatment of severe, active, and progressive rheumatoid arthritis in adults who have not previously been treated with methotrexate.

Juvenile Idiopathic Polyarthritis

• Treatment of active juvenile idiopathic polyarthritis (seropositive and seronegative) in children and adolescents over 12 years old and weighing more than 62.5 kg, who have had an inadequate response or intolerance to methotrexate.
• Treatment of extended oligoarthritis in children and adolescents over 12 years old and weighing more than 62.5 kg, who have had an inadequate response or intolerance to methotrexate.
• Treatment of psoriatic arthritis in adolescents over 12 years old and weighing more than 62.5 kg, who have had an inadequate response or intolerance to methotrexate.
• Treatment of enthesitis-related arthritis in adolescents over 12 years old and weighing more than 62.5 kg, who have had an inadequate response or intolerance to standard therapy.

Psoriatic Arthritis

• Treatment of active and progressive psoriatic arthritis in adults who have had an inadequate response to DMARDs.

Ankylosing Spondylitis

• Treatment of adults with active ankylosing spondylitis who have not achieved significant improvement with traditional therapy.

Non-radiographic Axial Spondyloarthritis

• Etanercept is indicated for the treatment of adults with severe non-radiographic axial spondyloarthritis who have had an inadequate response or resistance to standard therapy and have objective signs of disease activity confirmed by elevated C-reactive protein (CRP) levels and/or MRI data.

Psoriasis

• Treatment of adults with moderate to severe psoriasis who have contraindications or intolerance to other systemic therapy, including cyclosporine, methotrexate, or PUVA therapy.
• Treatment of children over 12 years old and weighing more than 62.5 kg with severe chronic psoriasis who have had an inadequate response or intolerance to other systemic or phototherapy.

Note: This product is included in the Essential Medicines List (EML).